Share on StockTwits

Smith & Nephew plc (LON:SN)‘s stock had its “buy” rating reiterated by equities researchers at Investec in a research report issued on Monday, Analyst Ratings Network reports. They currently have a GBX 1,100 ($18.48) price objective on the stock. Investec’s target price indicates a potential upside of 20.22% from the company’s current price.

SN has been the subject of a number of other recent research reports. Analysts at Credit Suisse reiterated a “neutral” rating on shares of Smith & Nephew plc in a research note on Friday. They now have a GBX 865 ($14.53) price target on the stock. Separately, analysts at Numis Securities Ltd reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Friday. They now have a GBX 1,000 ($16.80) price target on the stock. Finally, analysts at Deutsche Bank reiterated a “buy” rating on shares of Smith & Nephew plc in a research note on Friday. They now have a GBX 1,125 ($18.90) price target on the stock. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of GBX 921.33 ($15.48).

Shares of Smith & Nephew plc (LON:SN) opened at 924.50 on Monday. Smith & Nephew plc has a 1-year low of GBX 720.00 and a 1-year high of GBX 964.0001. The stock’s 50-day moving average is GBX 906.9 and its 200-day moving average is GBX 866.3. The company’s market cap is £8.250 billion.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.